Sebastien Couraud
Overview
Explore the profile of Sebastien Couraud including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
84
Citations
1261
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Feng X, Alcala K, Guida F, Goldberg M, Zins M, Leleu O, et al.
Lancet Reg Health Eur
. 2025 Feb;
51:101221.
PMID: 39968190
Background: We estimated the potential impact of different eligibility criteria for lung cancer screening in France, to inform a planned national pilot program. Methods: We simulated the French population by...
2.
Barthelemy D, Vigneron A, Rousset X, Guitton J, Grolleau E, Raffin M, et al.
FEBS Open Bio
. 2025 Jan;
PMID: 39887892
Non-small cell lung cancer (NSCLC) affects 10-50% of patients with epidermal growth factor receptor (EGFR) mutations. Osimertinib is a third-generation EGFR tyrosine kinase inhibitor (TKI) that radically changes the outcome...
3.
Swalduz A, Beau-Faller M, Planchard D, Mazieres J, Bayle-Bleuez S, Debieuvre D, et al.
Lung Cancer
. 2024 Dec;
199:108038.
PMID: 39616778
Background: BRAF V600E mutations occur in 2-5 % of advanced non-small cell lung cancer (NSCLC) patients. The dabrafenib-trametinib (D-T) combination was associated with improved and durable OS in patients in...
4.
Leleu O, Storme N, Basille D, Auquier M, Petigny V, Berna P, et al.
EBioMedicine
. 2024 Oct;
109:105396.
PMID: 39396424
Background: In prior randomised controlled trials, lung cancer screening using low-dose computed tomography (LDCT) has been shown to reduce lung cancer mortality and overall mortality. Despite these results, organised screening...
5.
Ferreira M, Swalduz A, Greillier L, Du Rusquec P, Curcio H, Raimbourg J, et al.
Lung Cancer
. 2024 Sep;
196:107934.
PMID: 39277916
Background: Capmatinib is a selective MET inhibitor with demonstrated efficacy in a phase II study of non-small cell lung cancer (NSCLC) patients harboring METex14 mutations. However, the real-world outcomes of...
6.
Grolleau E, Couraud S, Jupin Delevaux E, Piegay C, Mansuy A, de Bermont J, et al.
Respir Med Res
. 2024 Sep;
86:101136.
PMID: 39232429
Background: Pulmonary nodules are a common incidental finding on chest Computed Tomography scans (CT), most of the time outside of lung cancer screening (LCS). We aimed to evaluate the number...
7.
Leonce C, Guerriau C, Chalabreysse L, Duruisseaux M, Couraud S, Brevet M, et al.
Int J Mol Sci
. 2023 Nov;
24(21).
PMID: 37958668
Targeting EGFR alterations, particularly the L858R (Exon 21) mutation and Exon 19 deletion (del19), has significantly improved the survival of lung cancer patients. From now on, the issue is to...
8.
Meersseman C, Grolleau E, Freymond N, Wallet F, Gilbert T, Locatelli-Sanchez M, et al.
Respir Med Res
. 2023 Sep;
84:101026.
PMID: 37717386
Background: In COVID-19 patients, older age (sixty or older), comorbidities, and frailty are associated with a higher risk for mortality and invasive mechanical ventilation (IMV) failure. It therefore seems appropriate...
9.
Grolleau E, Candiracci J, Lescuyer G, Barthelemy D, Benzerdjeb N, Haon C, et al.
Biomolecules
. 2023 Aug;
13(8).
PMID: 37627320
The molecular profiling of circulating tumor DNA (ctDNA) is a helpful tool not only in cancer treatment, but also in the early detection of relapse. However, the clinical interpretation of...
10.
Barthelemy D, Lescuyer G, Geiguer F, Grolleau E, Gauthier A, Balandier J, et al.
Cancers (Basel)
. 2023 Mar;
15(5).
PMID: 36900363
Introduction: Progressive advanced non-small cell lung cancer (NSCLC) accounts for about 80-85% of all lung cancers. Approximately 10-50% of patients with NSCLC harbor targetable activating mutations, such as in-frame deletions...